News
Events
SciBase Holding AB announces the outcome of the exercise of warrants of series TO1
October 21, 2020SciBase Holding AB (publ) ("SciBase" or the "Company") today announces the outcome of the exercise of warrants of series TO1 which were issued in connection with the Company's 19,941,721 units issue on 26 March 2020. The outcome shows that a total of 18,220,264 warrants were exercised for subscription of 18,220,264 new shares in the Company, corresponding to 91.4 percent of the total number of warrants issued in series TO1.
Exercise price for warrants of series TO1 in SciBase Holding AB determined and the subscription period commence on 5 October 2020
October 2, 2020NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
Letter from the CEO, September 2020
September 29, 2020I trust that you have all had a safe and enjoyable summer. Given the high level of interest we have seen from you, our shareholders, I felt it time I update you on where we are as a Company and our plans for the near...Conversion of Warrants
September 25, 2020Information about conversion of warrants (TO1) is available in the investors pages (in Swedish). Please follow the link: http://investors.scibase.se/sv/information-avseende-omvandling-av-teckningsoptioner-to1New Clinical Studies show Improved Melanoma Detection by US clinicians with Nevisense
September 16, 2020STOCKHOLM, SWEDEN, - September 16, 2020 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that both the Journal of the American Academy of Dermatology (JAAD) and SKIN, The Journal of Cutaneous Medicine (SKIN), have published studies assessing the clinical impact of Nevisense. The studies compared the results of US clinicians evaluating atypical pigmented skin lesions (atypical moles) using visual evaluation only compared to visual evaluation and the Nevisense result combined.
SciBase’s Nevisense product included in infant study at Mount Sinai Hospital
August 26, 2020Stockholm, Sweden and New York, USA - August 26, 2020 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that they will participate in a clinical study to run parallel to the ACTIVATE study (sponsored by the Immune Tolerance Network and the NIAID/NIH), which is being conducted by the Department of Pediatric Allergy at Mount Sinai Hospital in New York.
- Load more news...